baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

MannKind Corporation/ US56400P7069 /

2024-05-07 9:05:52 PM	Chg. +0.0650	Volume	Bid9:05:52 PM	Ask9:05:52 PM	High	Low
4.4650USD	+1.48%	1.38 mill. Turnover: 5.65 mill.	4.4600Bid Size: 3,900	4.4700Ask Size: 13,500	4.5300	4.3800

GlobeNewswire 05-06 MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Tre...

GlobeNewswire 05-01 MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

GlobeNewswire 04-30 MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

GlobeNewswire 04-29 MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Susp...

GlobeNewswire 04-03 MannKind Repays Certain Debt Obligations

GlobeNewswire 03-26 MannKind Announces CFO Transition

GlobeNewswire 03-11 INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily ...

GlobeNewswire 03-05 MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATT...

GlobeNewswire 03-04 MannKind Corporation Announces Participation at Upcoming Conferences

GlobeNewswire 02-27 MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical ...

GlobeNewswire 02-20 MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on ...

GlobeNewswire 02-15 MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza...

GlobeNewswire 01-02 MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

GlobeNewswire 2023-12-28 MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-11-07 MannKind Corporation Reports 2023 Third Quarter Financial Results

GlobeNewswire 2023-11-06 MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Livi...

GlobeNewswire 2023-10-31 MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 202...

GlobeNewswire 2023-10-30 MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent

GlobeNewswire 2023-09-05 MannKind Corporation Announces Participation at Upcoming Conferences

GlobeNewswire 2022-03-28 MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

GlobeNewswire 2022-03-22 MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

GlobeNewswire 2022-03-08 MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire 2022-02-24 MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

GlobeNewswire 2022-02-24 Update on Tyvaso DPI™ New Drug Application

GlobeNewswire 2022-02-21 MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on ...

MannKind Corporation/ US56400P7069 /

If you wish to receive reply to your feedback, please provide your email address.